Symptomatic treatment of osteoarthrosis with two different oral preparations of naproxen.

Abstract

A new oral Naproxen retard preparation (750 mg once daily) was compared with a standard commercial formula (375 mg BID) in a population of 60 patients affected by osteoarthritis or rheumatoid arthritis. An assessment was made of the effects on the clinical parameters, inflammation indexes (ESR, PCR, urinary hydroxyproline) and general tolerance parameters… (More)

Topics

Cite this paper

@article{Lacovacci1989SymptomaticTO, title={Symptomatic treatment of osteoarthrosis with two different oral preparations of naproxen.}, author={F Lacovacci and Silvia Bosio and Gianmaria Venturino}, journal={Rivista europea per le scienze mediche e farmacologiche = European review for medical and pharmacological sciences = Revue europeenne pour les sciences medicales et pharmacologiques}, year={1989}, volume={11 3}, pages={263-9} }